Veracyte stock just dropped 22% to US$46.32, even though the quarter delivered what many long term investors say they want. Revenue reached US$150.3m and net income came in at US$25.5m, with adjusted earnings before interest, tax, depreciation and amortization at US$44m, equal to 29.2% of sales. That is a rich margin in diagnostics testing.

The short term verdict is clear on your screen. The longer term question is whether a business that now generates this level of profit and cash can justify trading well below some intrinsic value estimates. The rest of this earnings breakdown examines that gap.

Is Veracyte now a clear bargain after this 38.4% gap to the DCF value, or is the stock priced this way for a reason? Compare the current price, cash flows and P/E against our valuation analysis for Veracyte

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$150.3m vs. US$130.2m (up about 15%)
• Net Income, Q2 2026 vs. Q2 2025: US$25.5m vs. a loss of US$1.0m (returned to profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.32 vs. a loss of US$0.01 per share (moved from loss to positive earnings)
• Adjusted EBITDA Margin, Q2 2026 vs. Q2 2025: 29.2% of revenue vs. margin not disclosed for Q2 2025 (Q2 2026 reflects a high diagnostics testing margin)

If you prefer clean charts to scrolling through more text and raw figures, you can view a full visual breakdown of Veracyte, with a focus on its valuation picture, in the company report for Veracyte.

Veracyte’s Bull Story Meets Concrete Product Milestones

Bulls argue Veracyte can turn its oncology test portfolio into a broad, higher margin cancer platform. Q2 gives tangible proof points on that claim. Decipher and Afirma, the two core franchises, both posted double digit revenue and volume growth, supported by better average selling prices and lower no result rates. That directly supports the idea of deeper penetration rather than one off demand.

The thesis also leans heavily on new launches and evidence. In this area, Q2 lands several milestones. Prosigna is now commercially live in the U.S. and backed by Phase III OPTIMA data, with more than 100 institutional engagements, even though Medicare MolDX technical review and final pricing are still pending. TrueMRD, Veracyte’s minimal residual disease platform for bladder cancer, moved from concept to a reimbursed product with Medicare coverage and initial orders. Together with a 29.2% adjusted EBITDA margin, these data points illustrate how the bull story’s scale and profitability pillars are beginning to align with the reported results.

Compare these solid Q2 building blocks with how institutions are reacting. See the consensus price target analysis for Veracyte to check whether analysts think Veracyte’s current price lines up with this earnings story.

Veracyte Bear Case: Strong Print, Key Gaps Exposed

Bears argue Veracyte is over reliant on a few flagship tests and vulnerable to reimbursement and guideline shocks. Q2 partly supports that concern. Decipher remains a growth engine, yet management trimmed 2026 volume expectations after guidelines moved to de emphasize genomic tests in low risk active surveillance. That is an early example of concentration risk playing out in real time, even if the impact is only about 1% of planned volume.

Reimbursement caution also shows up. Prosigna is live in the U.S., but Medicare MolDX technical review and final pricing are still outstanding, and management excludes Prosigna revenue from full year guidance. TrueMRD has Medicare coverage, although commercial uptake is only just starting. Combined with a 22% one day share price drop, the market reaction suggests investors are still treating reimbursement and product concentration as unresolved risks despite solid margins and cash generation.

After a 22.5% one day share price drop and questions around reimbursement and product concentration, it is worth asking whether this is just the visible risk or only the first crack in Veracyte’s story. Review the independent risk scoring and see if other structural warning signs appear in the risk analysis for Veracyte which shows 1 important warning sign.

Stay Ahead Of Your Next Move

If Veracyte's sharp 22% share price drop and solid Q2 profitability have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value estimates and spot a more informed entry point. Once you are invested, organise your holdings with the Portfolio Command Center so you see the key developments that matter for your thesis instead of day to day noise. Over the longer term, compare your view on Veracyte with what other investors are thinking through the Community and test your ideas against a wide range of perspectives. By surfacing potential catalysts and risks early, you can make faster, clearer decisions and stay a step ahead of the market.

Seeking Alternatives Beyond Veracyte Now

Fresh stock ideas can start breaking out while you stay focused on one story. Use these screeners before the momentum flies and the best entry points get caught. Act now.

• Spot cash generative compounders early and review the 55 high quality undervalued stocks curated to highlight stocks where quality, balance sheets and valuation still line up before the crowd rushes in.
• Ride structural tech momentum instead of chasing hype and scan the 57 AI infrastructure stocks that surfaces companies powering the hardware and plumbing behind fast growing AI demand while it remains under the radar for now.
• Lock in steadier income streams while prices are still reasonable and check the 9 dividend fortresses designed to surface higher yielding businesses that pair resilience with meaningful cash payouts before yields start dropping.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.